Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
Public ClinicalTrials.gov record NCT04930094. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg and 150 mg Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) (GCAptAIN)
Study identification
- NCT ID
- NCT04930094
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 354 participants
Conditions and interventions
Conditions
Interventions
- Secukinumab 300 mg Biological
- Placebo Other
- Secukinumab 150 mg Biological
Biological · Other
Eligibility (public fields only)
- Age range
- 50 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 5, 2021
- Primary completion
- Apr 10, 2025
- Completion
- Feb 17, 2026
- Last update posted
- Mar 30, 2026
2021 – 2026
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| IRIS Research and Development | Plantation | Florida | 33324 | — |
| Sarasota Arthritis Res Ctr | Sarasota | Florida | 34239 | — |
| Novartis Investigative Site | Iowa City | Iowa | 52242 | — |
| University Of Iowa | Iowa City | Iowa | 52242 | — |
| Osteoporosis and Clinical Trial Ctr | Hagerstown | Maryland | 21740 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| West Tennessee Research Institute | Jackson | Tennessee | 38305 | — |
| Precision Comp Clin Research | Grapevine | Texas | 76051 | — |
| Advanced Rheumatology of Houston | Spring | Texas | 77382 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 94 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04930094, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04930094 live on ClinicalTrials.gov.